When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MIST - Milestone Pharma provides update on late stage etripamil study; secures $25M in equity
Milestone Pharmaceuticals Inc.
The FDA signs off Milestone Pharmaceuticals's (NASDAQ:MIST) plan to modify the ongoing NODE-301B study of etripamil, renamed as RAPID study, and include time to conversion over the first 30 minutes after drug administration, as the primary endpoint.
More news on: Milestone Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, ,